Table 10.
CsA AUC (0–12) compliances within therapeutic ranges in patients with IFTA (1–5 years and >5 years post-transplantation groups).
| Number of Subjects with IFTA | 1–5 Years (CsA + MMF) |
1–5 Years (CsA) |
Number of Subjects with IFTA | >5 Years (CsA + MMF) |
>5 Years (CsA) |
Total | |
|---|---|---|---|---|---|---|---|
| 10 (19.6%) Out of 51 |
1 (33.33%) Out of 3 |
20 (20.8%) Out of 96 |
8 (17.4%) Out of 46 |
39 (19.9%) Out of 196 |
|||
| Therapeutic ranges | < 3.04 mg/h/L | 4 (40.0%) |
- | < 2.69 mg/h/L | 11 (55.0%) |
2 (25.0%) |
17 (8.7%) |
| 3.05–3.75 mg/h/L | 3 (30.0%) |
1 (100.0%) |
2.70–2.98 mg/h/L | 1 (5.0%) |
3 (37.5%) |
8 (4.1%) |
|
| > 3.76 mg/h/L | 3 (30.0%) |
- | > 2.99 mg/h/L | 8 (40.0%) |
3 (37.5%) |
14 (7.1%) |
IFTA—interstitial fibrosis and tubular atrophy; CsA—cyclosporine; MMF—mycophenolate mofetil.